EVALUATION OF THE EFFECT OF PHARMACOGENETIC DOSING OF WARFARIN: SHOULD NON-RANDOMIZED CLINICAL STUDIES BE CONSIDERED?

被引：0
|
作者：
Janzic, A. [1 ]
Locatelli, I [1 ]
机构：
[1] Univ Ljubljana, Fac Pharm, Ljubljana, Slovenia
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.1687
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV20
引用
收藏
页码：A639 / A639
页数：1
相关论文
共 50 条
  • [1] A Pharmacogenetic versus a Clinical Algorithm for Warfarin Dosing
    Kimmel, Stephen E.
    French, Benjamin
    Kasner, Scott E.
    Johnson, Julie A.
    Anderson, Jeffrey L.
    Gage, Brian F.
    Rosenberg, Yves D.
    Eby, Charles S.
    Madigan, Rosemary A.
    McBane, Robert B.
    Abdel-Rahman, Sherif Z.
    Stevens, Scott M.
    Yale, Steven
    Mohler, Emile R., III
    Fang, Margaret C.
    Shah, Vinay
    Horenstein, Richard B.
    Limdi, Nita A.
    Muldowney, James A. S., III
    Gujral, Jaspal
    Delafontaine, Patrice
    Desnick, Robert J.
    Ortel, Thomas L.
    Billett, Henny H.
    Pendleton, Robert C.
    Geller, Nancy L.
    Halperin, Jonathan L.
    Goldhaber, Samuel Z.
    Caldwell, Michael D.
    Califf, Robert M.
    Ellenberg, Jonas H.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (24): : 2283 - 2293
  • [2] Non-randomized studies should be considered for assessing surgical techniques in rectal prolapse: prospective cohort study
    Lee, M. J.
    Dimairo, M.
    Edwards, J.
    Hawkins, D. J.
    Hind, D.
    Knowles, C. H.
    Hooper, R.
    Brown, S. R.
    [J]. COLORECTAL DISEASE, 2020, 22 (12) : 2170 - 2180
  • [3] Clinical and pharmacogenetic data used to estimate warfarin dosing
    不详
    [J]. PHARMACOGENOMICS, 2009, 10 (04) : 519 - 519
  • [4] Non-randomized evaluation studies (TREND)
    Vallve, Carles
    Artes, Maite
    Cobo, Erik
    [J]. MEDICINA CLINICA, 2005, 125 : 38 - 42
  • [5] Comparative accuracy of pharmacogenetic warfarin dosing algorithms and the warfarin dosing label plus clinical judgment
    Labinov, Yana
    DiDomenico, Robert
    Nutescu, Edith A.
    Cavallari, Larisa H.
    [J]. PHARMACOTHERAPY, 2013, 33 (10): : E190 - E190
  • [6] A Randomized Trial of Pharmacogenetic Warfarin Dosing in Naive Patients with Non-Valvular Atrial Fibrillation
    Pengo, Vittorio
    Zambon, Carlo-Federico
    Fogar, Paola
    Padoan, Andrea
    Nante, Giovanni
    Pelloso, Michela
    Moz, Stefania
    Frigo, Anna Chiara
    Groppa, Francesca
    Bozzato, Dania
    Tiso, Enrico
    Gnatta, Elisa
    Denas, Gentian
    Jose, Seena Padayattil
    Padrini, Roberto
    Basso, Daniela
    Plebani, Mario
    [J]. PLOS ONE, 2015, 10 (12):
  • [7] Clinical and economic consequences of pharmacogenetic-guided dosing of warfarin
    Verhoef, Talitha I.
    Schalekamp, Tom
    Redekop, William K.
    de Boer, Anthonius
    Maitland-van der Zee, Anke-Hilse
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2010, 10 (04) : 375 - 378
  • [8] Pharmacogenetic dosing of warfarin in the Han-Chinese population: a randomized trial
    Wen, Ming-Shien
    Chang, Kuan-Cheng
    Lee, Tsong-Hai
    Chen, Ying-Fu
    Hung, Kuo-Chun
    Chang, Yeu-Jhy
    Liou, Chia-Wei
    Chen, Jin-Jer
    Chang, Chien-Hung
    Wang, Chao-Yung
    Jeng, Jiann-Shing
    Chuang, Hui-Ping
    Chen, Ying-Ting
    Chen, Chien-Hsiun
    Wu, Jer-Yuarn
    Chen, Yuan-Tsong
    Lee, Ming Ta Michael
    [J]. PHARMACOGENOMICS, 2017, 18 (03) : 245 - 253
  • [9] Clinical benefits of pharmacogenetic algorithm-based warfarin dosing: meta-analysis of randomized controlled trials
    Li, Xiaoqi
    Yang, Jie
    Wang, Xuyun
    Xu, Qiang
    Zhang, Yuxiao
    Yin, Tong
    [J]. THROMBOSIS RESEARCH, 2015, 135 (04) : 621 - 629
  • [10] Anticoagulation endpoints with clinical implementation of warfarin pharmacogenetic dosing in a real-world setting: A proposal for a new pharmacogenetic dosing approach
    Arwood, M. J.
    Deng, J.
    Drozda, K.
    Pugach, O.
    Nutescu, E. A.
    Schmidt, S.
    Duarte, J. D.
    Cavallari, L. H.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (05) : 675 - 683
12345